Bioanalytical Performance of Novel Protein-Free Blockers and Heterophilic Antibody Interference Blockers for the IVD Industry and Clinical Diagnostics

Tuesday, July 25
11 – 11:20 a.m.
Exhibit Hall Theater 2
Supported by Fapon Biotech


The lecture will provide guided insights into the tremendous utility of Fapon’s recently developed novel protein-free blockers and heterophilic antibody interference blockers to develop high performance, bioanalytically superior, and highly accurate immunoassays for clinical diagnostics. The protocols, which could be employed by in vitro diagnostic manufacturers and clinical scientists to develop high-sensitivity immunoassays obviating the interference from heterophilic antibodies, would be presented for multifarious immunoassay formats, such as chemiluminescence immunoassays and ELISA, together with the results.

The superior bioanalytical performance of our products will be presented along with their mechanism of action. Our protein-free blocker is a chemically synthesized and much smaller molecule in comparison to conventional blockers like bovine serum albumin (BSA), which leads to critically improved blocking of non-specific binding sites on the solid surface. We have the most diverse range of heterophilic antibody interference blockers for a wide range of immunoassay formats.


Sandeep K. Vashist
Senior Global IVD Product Director (EU), Fapon Biotech, Inc

Conference registration is now open

Check out the scientific sessions at ADLM 2024.  Register and start planning your schedule today.

Explore the conference program

ADLM 2024 offers something for everyone in laboratory medicine, from Plenaries featuring world-renowned scientists to intimate Roundtables.